Finance

Lists
Why is CRBP up 2,09%?
Dive Deeper
CRBP:NASDAQ
Corbus Pharmaceuticals Holdings Inc
USD 5,38
+2,09%
(+0,11) 1D
USD 5,45
+1,30% (+0,070)
After hours
Closed: 9 Okt., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRBP...
Open
USD 5,25
High
USD 5,61
Low
USD 5,17
Mkt. cap
104,06 m
Avg. vol.
1,18 m
Volume
872,80 k
52-wk high
USD 20,56
52-wk low
USD 5,14
EPS
-USD 6,17
Beta
2,63
Shares outstanding
19,34 m
No. of employees
36
Open
USD 5,25
High
USD 5,61
Low
USD 5,17
Mkt. cap
104,06 m
Avg. vol.
1,18 m
Volume
872,80 k
52-wk high
USD 20,56
52-wk low
USD 5,14
EPS
-USD 6,17
Beta
2,63
Shares outstanding
19,34 m
No. of employees
36
News stories
From web sources and news partners
About Corbus Pharmaceuticals Holdings Inc
CEO-
Employees36
Founded01 Jan. 2009
Headquarters-
Sector-
Websitecorbuspharma.com
Analyst ratings
Based on 7 analysts giving stock ratings to CRBP in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for CRBP in the last 3 months.
Highest
Current USD 5,38
USD 48,00 (+792,19%)
Average
USD 36,67 (+581,60%)
Lowest
USD 30,00 (+457,62%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Driscoll
Wedbush
Buy
Reiterated
USD 30,00
+457,6%
09/15/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
USD 35,00
+550,6%
09/15/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
09/14/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
USD 38,00
+606,3%
09/14/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
USD 33,00
+513,4%
09/14/2026
Brian Abrahams
RBC Capital
Buy
Maintained
USD 36,00
+569,1%
08/12/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
USD 48,00
+792,2%
08/07/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
USD 48,00
+792,2%
08/07/2026
Paul Jeng
Guggenheim
Buy
Maintained
USD 45,00
+736,4%
06/02/2026
Unknown Analyst
Wedbush
Buy
Reiterated
USD 38,00
+606,3%
05/13/2026
Maury Raycroft
Jefferies
Buy
Maintained
USD 33,00
+513,4%
05/12/2026
Unknown Analyst
B. Riley Securities
Buy
Reiterated
USD 28,00
+420,4%
04/10/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
-
-
Cost of goods sold
20,86 m
18,41 m
19,82 m
31,18 m
Cost of revenue
20,86 m
18,41 m
19,82 m
31,18 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,56 m
3,56 m
4,48 m
5,02 m
Operating expense
3,56 m
3,56 m
4,48 m
5,02 m
Total operating expenses
24,42 m
21,97 m
24,30 m
36,19 m
Operating income
-24,42 m
-21,97 m
-24,30 m
-36,19 m
Other non operating income
-50,00 k
-1,10 m
-67,00 k
-11,00 k
EBT including unusual items
-23,34 m
-20,56 m
-22,97 m
-35,04 m
EBT excluding unusual items
-23,34 m
-21,66 m
-22,97 m
-35,04 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-23,34 m
-20,56 m
-22,97 m
-35,04 m
Net profit margin
-
-
-
-
Earnings per share
-1,90
-1,25
-1,23
-1,81
Interest and investment income
1,12 m
1,41 m
1,40 m
1,16 m
Interest expense
-
-
-
-
Net interest expenses
1,12 m
1,41 m
1,40 m
1,16 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-24,37 m
-21,92 m
-24,26 m
-36,14 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme